Welcome to our dedicated page for Annovis Bio news (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio stock.
Annovis Bio, Inc. develops buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. News about ANVS commonly centers on clinical development of buntanetap, peer-reviewed publications, biomarker data, safety findings, and scientific presentations related to the company’s multi-protein approach to neurodegeneration.
Recurring updates also cover intellectual-property protection for buntanetap and related compounds, collaborations that add digital biomarker technology to Parkinson’s disease research, corporate financing, annual financial results, and other public-company developments tied to funding, governance, and clinical-regulatory disclosure.
Annovis Bio (ANVS) has received Central IRB approval to initiate a Phase 2 clinical study targeting early Parkinson's disease (PD) and Alzheimer's disease (AD) patients. The study will involve 68 patients over four weeks, assessing the lead compound, ANVS401, for its effects on nerve cell death and cognitive functions. The trial aims to understand safety, tolerability, and the potential reversal of toxic cascades affecting nerve cells. CEO Maria Maccecchini expressed optimism about staying on schedule to complete the study by Q1 2021, despite initial delays related to COVID-19.
Annovis Bio Inc. (NYSE American: ANVS) announced the successful completion of a chronic toxicology study for its lead compound, ANVS401, with no adverse side effects reported in rats. Funded by a $1.7 million NIH grant, this six-month study corroborates previous positive results from shorter studies. CEO Maria Maccecchini highlighted this milestone as critical for advancing long-term human studies. Ongoing safety studies on dogs are anticipated to yield results in Q3 2020, supporting Annovis's ongoing clinical trials for Alzheimer's and Parkinson's diseases.
On June 9, 2020, Annovis Bio Inc. (NYSE American: ANVS) announced that its CEO, Maria Maccecchini, Ph.D., and CFO, Jeff McGroarty, MBA, CPA, will present virtually at the June 2020 Virtual Summer Investor Summit from June 9-12, 2020. The presentation is scheduled for June 10 at 10:55 a.m. ET, followed by a live Q&A session. Annovis Bio focuses on developing treatments for Alzheimer’s and Parkinson’s diseases, with ongoing clinical studies to improve neurodegeneration. Investors can register for the summit and access the live webcast online.
On June 2, 2020, Annovis Bio Inc. (NYSE American: ANVS) announced that the European Patent Office granted a patent for a method to treat Alzheimer's disease with its lead compound, ANVS401. This patent complements the existing US patent for Parkinson's Disease. CEO Maria Maccecchini highlighted plans for additional patents targeting various neurodegenerative diseases. Annovis Bio is conducting two Phase 2 studies of ANVS401 to demonstrate its efficacy in preserving nerve cell function in Alzheimer's and Parkinson's patients.
Annovis Bio (NYSE American: ANVS) announced that its 2020 Annual Meeting of Stockholders will be held virtually on June 3, 2020, at 10:00 a.m. ET. Shareholders are encouraged to attend and vote using their Virtual Control Number. The Notice of Annual Meeting, Proxy Statement, and Annual Report for the year ended December 31, 2019, are accessible online. The company is focused on developing treatments for neurodegenerative diseases, including Alzheimer’s and Parkinson’s, with ongoing clinical trials aimed at improving patient outcomes.
Summary not available.
Summary not available.